Generic version of Namenda Approved for Dementia of Alzheimer
July 13, 2015 - Dr. Reddy’s announced the launch of its AB-rated generic equivalent to Namenda (memantine) tablets manufactured by Actavis. Namenda was originally approved by the U.S. Food and Drug Administration in 2003 for the treatment of moderate to severe dementia of Alzheimer’s type. In June 2013, Actavis launched Namenda XR, a once-daily follow-on product in an effort to switch patents to a different version of the medication. The District court ruled that Actavis had to make sure the original Namenda remained on the market and available to patients. It should be noted that, a settlement agreement allows several manufacturers to launch generics to Namenda.
Dosage forms for Dr. Reddy’s generic memantine will be available in 5mg and 10mg tablets.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.